| High-income North America |
| Prevalence |
131 803 (107432–159399) |
199 970 (157 616–246 093) |
216420 (168 746–265 722) |
216711 (171 356–265789) |
789737 (632 514–948 176) |
| Cases per 100000 |
767 (625–927) |
890 (701–1095) |
920 (717–1129) |
920 (727–1128) |
867 (695–1041) |
| YLD |
51 974 (37 050–69 051) |
75 662 (53 611–104 677) |
79999 (55802–109880) |
77882 (54 747–107 040) |
295570 (211 251–403410) |
| Rate per 100 000 |
302 (216–402) |
337 (238–466) |
340 (237–467) |
331 (232–454) |
325 (232–443) |
| Western Europe |
| Prevalence |
126 468 (100 007–156 598) |
188 957 (144 255–237 135) |
196335 (151 269–242173 |
202926 (1 57 762–249 314) |
739 764 (574 153–903 671) |
| Cases per 100000 |
712 (563–882) |
803 (613–1008) |
845 (651–1042) |
865 (673–1063) |
802 (622–979) |
| YLD |
48 964 (34429–67 257) |
70 905 (49 050–98 578) |
72145 (49296–98731) |
72 754 (50 216–100 092) |
274 710 (192 230–373 788) |
| Rate per 100 000 |
276 (194–379) |
301 (209–419) |
310 (212–425) |
310 (214–427) |
298 (208–405) |
| Central Europe, Eastern |
| Europe, and Central Asia |
|
|
|
|
| Prevalence |
189 861 (156 308–226 756) |
275 179 (221 331–336 004) |
256 698 (207 995–311 453) |
247 331 (203 706–297 748) |
1 004098 (839 357–1 194942) |
| Cases per 100000 |
837 (689–1000) |
1001 (805–1222) |
1066 (864–1293) |
1083 (892–1304) |
980 (820–1167) |
| YLD |
83 351 (60 394–108 332) |
117909 (86 351–153 388) |
108160 (78 760–144448) |
102209 (75 128–136 169) |
427 137 (315 890–554 788) |
| Rate per 100000 |
368 (266–478) |
429 (314–558) |
449 (327–600) |
448 (329–596) |
417 (308–542) |
| Latin America and the Caribbean |
| Prevalence |
449 630 (370 510–548 055) |
575 028 (459 495–713 720) |
609379 (483 554–749 149) |
672 801 (550 138–818 731) |
2 420 438 (1 972 412–2917913) |
| Cases per 100000 |
1106 (911 –1348) |
1163 (929–1443) |
1237 (981–1521) |
1347 (1101–1639) |
1213 (988–1462) |
| YLD |
196 721 (145 687–256 747) |
245 611 (178 296–324 113) |
253267 (184956–339349) |
267238 (198 161–357 961) |
1 013 135 (747 175–1338725) |
| Rate per 100000 |
484 (358–631) |
497 (361–655) |
514 (375–689) |
535 (397–717) |
508 (374–671) |
| Southeast Asia, East Asia, and Oceania |
| Prevalence |
737 521 (605 450–893 982) |
945 540 (750 994–1 164 348) |
958185 (773 663–1 184098) |
962 589 (783 522–1 177 510) |
3 793 040 (3141 571–4560916) |
| Cases per 100000 |
664 (545–804) |
701 (557–863) |
703 (567–868) |
692 (563–846) |
687 (569–826) |
| YLD |
331 971 (248 485–440 416) |
420 846 (308 919–561 459) |
423461 (308930–564083) |
419 264 (308 153–556 904) |
1 681 681 (1267440–2163937) |
| Rate per 100000 |
299 (224–396) |
312 (229–416) |
310 (227–414) |
301 (221–400) |
305 (230–392) |
| South Asia |
| Prevalence |
1 134129 (892519–1 402382) |
1 592310 (1216 048–2021 679) |
1 626 659 (1 248 656–2 046 161) |
1 626 693 (1 279 219–2 022 196) |
6 207 938 (5071 432–7483407) |
| Cases per 100000 |
804 (633–994) |
889 (679–1129) |
915 (702–1151) |
914 (719–1136) |
875 (715–1055) |
| YLD |
547600 (384538–732918) |
760878 (545 412–1 049 013) |
772 626 (562 422–1 054172) |
760804 (549 690–1 019 818) |
2 952 475 (2180425–3869281) |
| Rate per 100 000 |
388 (273–519) |
425 (304–586) |
434 (316–593) |
428 (309–573) |
416 (307–545) |
| Sub-Saharan Africa |
| Prevalence |
1 324612 (1 044953–1 668665) |
1 445 699 (1 089 817–1 874924) |
1 327 538 (1 012 314–1 723 209) |
1 174 404 (905 551–1 483 284) |
5 610 340 (4407396–7044475) |
| Cases per 100000 |
1027 (810–1294) |
980 (739–1271) |
1017 (776–1321) |
1062 (819–1341) |
1016 (799–1276) |
| YLD |
631 083 (455159–836628) |
654 829 (453 942–909 475) |
594 123 (408 058–828 262) |
513862 (358 361–705 617) |
2 561 263 (1 817398–3446823) |
| Rate per 100 000 |
489 (353–649) |
444 (308–617) |
455 (313–635) |
465 (324–638) |
464 (329–624) |
| North Africa and the Middle East |
| Prevalence |
529020 (425793–647712) |
605 404 (476 471–745 640) |
513 903 (406 382–628 706) |
439 954 (351 097–534 851) |
2216563 (1 779 281–2 654 106) |
| Cases per 100000 |
1025 (825–1255) |
980 (771–1207) |
908 (718–1111) |
838 (669–1019) |
942 (756–1128) |
| YLD |
236221 (173908–315055) |
264 780 (193 166–360 277) |
224 422 (163 680–298 144) |
190429 (137 334–255 005) |
975171 (719368–1 300 365) |
| Rate per 100000 |
458 (337–611) |
429 (313–583) |
397 (289–527) |
363 (262–486) |
415 (306–553) |
| Global |
| Prevalence |
4704742 (3906017–5688824) |
5951 176 (4 780 635–7 281 786) |
5 825 559 (4 699 604–7 042 917) |
5 674377 (4 682 960–6 831 607) |
23251 109 (19477175–27607857 |
| Cases per 100000 |
867 (720–1048) |
900 (723–1101) |
916 (739–1107) |
920 (760–1108) |
896 (751–1064) |
| YLD |
2161 753 (1 622637–2784049) |
2 661 547 (1 961 247–3478308) |
2 576 792 (1 943 858–3 419 294) |
2 456 333 (1 856830–3223372) |
10371 105 (7852990–13253967) |
| Rate per 100000 |
398 (299–513) |
403 (297–526) |
405 (306–537) |
398 (301–523) |
400 (303–511) |
